Sign in

CIK 0001984086 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Septerna, Inc.

Sign in to watch
Ticker
SEPN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
843891440
Phone
650-338-3533
Business address
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$4,210,085
in 3 filings, $4.2M under 10b5-1 plans

Net −$4,210,085. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Ezekowitz Alan −$3.9M Director sold 70% of stake
  2. Bhatt Elizabeth −$150K President and COO sold 2% of stake
  3. Long Daniel D. −$126K SVP, Drug Discovery sold 3% of stake
Date Insider Transaction Shares Price Value Owned after
2024-10-28 RA CAPITAL MANAGEMENT, L.P. Director Conversion · Series B Preferred Stock −14,598,896 0
2024-10-28 RA CAPITAL MANAGEMENT, L.P. Director Conversion · Series B Preferred Stock −9,732,596 0
2024-10-28 Third Rock Ventures V, L.P. 10% owner Conversion +4,790,773 5,845,091
2024-10-28 Third Rock Ventures V, L.P. 10% owner Conversion +2,872,956 2,872,956
2024-10-28 Third Rock Ventures V, L.P. 10% owner Purchase +370,500 $18.00 $6.7M 6,215,591
2024-10-28 Third Rock Ventures V, L.P. 10% owner Purchase +279,500 $18.00 $5.0M 3,152,456
2024-10-28 Third Rock Ventures V, L.P. 10% owner Conversion · Series A Preferred Stock −41,250,000 0
2024-10-28 Third Rock Ventures V, L.P. 10% owner Conversion · Series B Preferred Stock −24,737,017 0

Page 8 of 8 · 148 trades